Relay’s SHP2 Runs Aground As Roche Pulls Out Of Development Deal
Executive Summary
Relay said in an SEC filing that Roche terminated the deal to develop migoprotafib, though Roche emphasized that it was not due to any emerging clinical safety concerns.